Analysts expect Phibro Animal Health Corp (NASDAQ:PAHC) to report $0.34 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Phibro Animal Health’s earnings. The lowest EPS estimate is $0.33 and the highest is $0.34. Phibro Animal Health posted earnings per share of $0.46 in the same quarter last year, which would indicate a negative year-over-year growth rate of 26.1%. The business is scheduled to announce its next quarterly earnings report on Monday, August 26th.
According to Zacks, analysts expect that Phibro Animal Health will report full-year earnings of $1.52 per share for the current fiscal year, with EPS estimates ranging from $1.50 to $1.55. For the next financial year, analysts anticipate that the company will report earnings of $1.61 per share, with EPS estimates ranging from $1.48 to $1.75. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Phibro Animal Health.
Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Monday, May 6th. The company reported $0.39 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.43 by ($0.04). The company had revenue of $205.70 million for the quarter, compared to the consensus estimate of $214.94 million. Phibro Animal Health had a return on equity of 33.77% and a net margin of 8.12%. The firm’s revenue was down 1.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.46 earnings per share.
PAHC has been the subject of several analyst reports. Guggenheim reiterated a “buy” rating and issued a $95.00 target price (up previously from $90.00) on shares of VF in a report on Thursday, May 23rd. BidaskClub upgraded shares of Westport Fuel Systems from a “hold” rating to a “buy” rating in a report on Friday, July 12th. ValuEngine downgraded shares of Verso from a “hold” rating to a “sell” rating in a report on Thursday, May 23rd. Barclays reiterated a “hold” rating on shares of Bank of Montreal in a report on Tuesday, June 11th. Finally, Zacks Investment Research upgraded shares of Triple-S Management from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a report on Monday, April 29th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $41.50.
Shares of Phibro Animal Health stock traded down $0.42 during trading hours on Wednesday, reaching $29.97. The company’s stock had a trading volume of 73,639 shares, compared to its average volume of 165,654. Phibro Animal Health has a one year low of $27.32 and a one year high of $54.62. The stock has a market cap of $1.21 billion, a P/E ratio of 17.22, a P/E/G ratio of 4.26 and a beta of 0.74. The business has a fifty day simple moving average of $30.40. The company has a quick ratio of 1.98, a current ratio of 3.41 and a debt-to-equity ratio of 1.48.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, June 26th. Investors of record on Wednesday, June 5th were issued a dividend of $0.12 per share. The ex-dividend date of this dividend was Tuesday, June 4th. This represents a $0.48 dividend on an annualized basis and a yield of 1.60%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 27.59%.
A number of hedge funds and other institutional investors have recently bought and sold shares of PAHC. Truvestments Capital LLC bought a new position in Phibro Animal Health during the first quarter worth about $36,000. Advisory Services Network LLC boosted its position in Phibro Animal Health by 20.4% during the fourth quarter. Advisory Services Network LLC now owns 2,195 shares of the company’s stock worth $71,000 after purchasing an additional 372 shares during the period. Quantamental Technologies LLC boosted its position in Phibro Animal Health by 26.0% during the first quarter. Quantamental Technologies LLC now owns 2,358 shares of the company’s stock worth $78,000 after purchasing an additional 487 shares during the period. BNP Paribas Arbitrage SA boosted its position in Phibro Animal Health by 926.8% during the first quarter. BNP Paribas Arbitrage SA now owns 4,713 shares of the company’s stock worth $156,000 after purchasing an additional 4,254 shares during the period. Finally, Advisors Asset Management Inc. boosted its position in Phibro Animal Health by 136.0% during the first quarter. Advisors Asset Management Inc. now owns 5,984 shares of the company’s stock worth $197,000 after purchasing an additional 3,448 shares during the period. Institutional investors and hedge funds own 50.28% of the company’s stock.
Phibro Animal Health Company Profile
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Recommended Story: Green Investing
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.